Increased liability of tramadol-warfarin interaction in individuals with mutations in the cytochrome p450 2D6 gene
2004 (English)In: European Journal of Clinical Pharmacology, ISSN 0031-6970, Vol. 60, no 5, 369-372 p.Article in journal (Refereed) Published
Objective This study aimed to investigate the importance of cytochrome P450 enzymes for the reported interaction between tramadol and warfarin.Materials and methods Cases of suspected interaction between tramadol and warfarin resulting in International Normalised Ratios increases that were reported to the Swedish Adverse Drug Reactions Advisory Committee until March 2003 were included. Ten cases had been genotyped for known polymorphisms of CYP2D6, CYP2C9 and CYP2C19.Results Seven of ten patients carried defective CYP2D6 alleles (population prevalence 42.2%) (one-sided binomial test, P=0.07). A further patient received concomitant drug treatments that may have resulted in CYP2D6 enzyme inhibition.Conclusion The liability to an interaction between tramadol and warfarin may be related to the CYP2D6 activity.
Place, publisher, year, edition, pages
2004. Vol. 60, no 5, 369-372 p.
Tramadol, Warfarin, Cytochrome P450
Pharmacology and Toxicology
Research subject Clinical Pharmacology
IdentifiersURN: urn:nbn:se:uu:diva-86592DOI: 10.1007/s00228-004-0783-7PubMedID: 15197521OAI: oai:DiVA.org:uu-86592DiVA: diva2:126465